CVS
CVS came to play
CVS Health opened its books and, unlike a lot of corporate earnings calls, this one didn’t need a translation app. Revenue for the second quarter climbed to $106.1 billion, up 7.3% from a year ago, while GAAP diluted EPS came in at $2.31 and adjusted EPS hit $2.58.
That’s the kind of report that says, “Hey, we’re not just surviving the healthcare maze — we’re finding the exits.”
The real headline: guidance got better
The part investors will probably care about most is the upgrade to full-year 2026 guidance. CVS raised:
- GAAP diluted EPS guidance to $6.84–$7.04 from $6.24–$6.44
- Adjusted EPS guidance to $7.90–$8.10 from $7.30–$7.50
- Cash flow from operations to at least $11.5 billion from at least $9.5 billion
That last one is the money shot. More cash flow means more flexibility — for debt, dividends, reinvestment, or just making the balance sheet look less like it had a rough night.
Why investors should care
CVS has been one of those stocks where every earnings print feels like a health checkup: blood pressure, pulse, and maybe a stress test. A better revenue print plus higher profit and cash-flow guidance suggests the company’s core businesses are doing enough to justify more optimism.
Big picture: if CVS can keep turning volume into cash, the market may be less interested in the drama and more interested in the recovery story.